The lower all-cause mortality in the GLP-1 receptor agonist group compared with the DPP-4 inhibitor group among patients with diabetes and advanced-stage CKD or ESKD in our study is in agreement with the findings of Palmer et al.7 This evidence concerns the gene DPP4 and diabetes mellitus.